within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX22_Leniolisib;

model Leniolisib
  extends Pharmacolibrary.Drugs.ATC.L.L03AX22;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L03AX22</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Leniolisib is an oral selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, used for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency disorder. It is approved for use in the United States and the European Union in patients aged 12 years and older with APDS.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for leniolisib reported in APDS patients (male and female, ages 12 and older) after oral administration of a 70 mg twice daily dose.</p><h4>References</h4><ol><li><p>Pearson, D, et al., &amp; Walles, M (2019). . <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 49(8) 953–960. DOI:<a href=\"https://doi.org/10.1080/00498254.2018.1523488\">10.1080/00498254.2018.1523488</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30215545/\">https://pubmed.ncbi.nlm.nih.gov/30215545</a></p></li><li><p>De Buck, S, et al., &amp; Woessner, R (2018). CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib. <i>Biopharmaceutics &amp; drug disposition</i> 39(8) 394–402. DOI:<a href=\"https://doi.org/10.1002/bdd.2157\">10.1002/bdd.2157</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30171694/\">https://pubmed.ncbi.nlm.nih.gov/30171694</a></p></li><li><p>Rao, VK, et al., &amp; Burkhart, C (2017). Effective &quot;activated PI3Kδ syndrome&quot;-targeted therapy with the PI3Kδ inhibitor leniolisib. <i>Blood</i> 130(21) 2307–2316. DOI:<a href=\"https://doi.org/10.1182/blood-2017-08-801191\">10.1182/blood-2017-08-801191</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28972011/\">https://pubmed.ncbi.nlm.nih.gov/28972011</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Leniolisib;
